m6A RNA methylation regulators contribute to progression and impact the prognosis of breast cancer

N6-methyladenosine (m6A) is the most commonly modified form of mRNA. M6A RNA methylation regulators are proved to be expressed clearly in some cancers by plenty of studies. Moreover, they also are proved to be indirectly involved in the growth of cancers. However, it remains unclear that the role of m6A RNA methylation regulator in the prognosis of breast cancer (BRCA). The data that we used in this study is the mRNA expression data obtained from the corresponding clinical information and the Tumor Genome Atlas (TCGA) database. And the goal we used the Wilcoxon rank-sum test was to evaluate the difference in the expression of m6A RNA methylation regulators in the normal group and the tumor group, and analyze the correlation between m6A RNA methylation regulators. We identified two subgroups of BRCA (cluster1 and 2) by using the K-mean algorithm and analyzing the correlation between clinic information and subgroups. The LASSO regression model then was used to figure out three m6A RNA methylation regulators, namely YTHDF3, ZC3H13, and HNRNPC. The riskScore of each patient was calculated according to the regression coefficients of the three m6A RNA methylation regulators. Base on the riskScore, we divided the patients into two groups, the high-risk group, and the low-risk group. After analyzing, we found that the overall survival rate (OS) of the low-risk group was higher than that of the other group. We conducted a univariate and multi-factor independent prognostic analysis of riskScore and three m6A RNA methylation regulators, and found that riskScore has a significant correlation with BRCA. In conclusion, the m6A RNA methylation regulator is closely related to the development of BRCA, and the prognostic factor riskScore obtained from the regression of the expression of the three m6A RNA methylation regulators in the human body are likely to guide the individualization of BRCA patients A useful prognostic biomarker for treatment.